CompletedPhase 2NCT01224028

A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Astellas Pharma Inc
Principal Investigator
Use Central Contact
Astellas Pharma Inc
Intervention
Tacrolimus(drug)
Enrollment
40 enrolled
Eligibility
18-70 years · All sexes
Timeline
20102011

Study locations (1)

Collaborators

Astellas Pharma Korea, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01224028 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy

← Back to all trials